| [1] |
Dixon S, Hill H, Flight L, et al. Cost-effectiveness of robot-assisted radical cystectomy vs open radical cystectomy for patients with bladder cancer[J]. JAMA Netw Open, 2023, 6(6): e2317255. DOI: 10.1001/jamanetworkopen.2023.17255.
|
| [2] |
Psutka SP. Prehabilitation: a multidimensional adjunct to comprehensive personalized oncologic care. But, can we make it pragmatic?[J]. Eur Urol Focus, 2024, 10(1): 1-3. DOI: 10.1016/j.euf.2024.02.001.
|
| [3] |
Briggs LG, Parke SC, Beck KL, et al. Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: a scoping review of randomized clinical trials[J]. Cancer, 2025, 131(1): e35608. DOI: 10.1002/cncr.35608.
|
| [4] |
Checcucci E, Veccia A, Puliatti S, et al. Metaverse in surgery—origins and future potential[J]. Nat Rev Urol, 2024: 1-14. DOI: 10.1038/s41585-024-00941-4.
|
| [5] |
Geissler ME, Bereuter JP, Geissler RB, et al. Comparison of distance versus in-person laparoscopy training using a low-cost laparoscopy simulator-a randomized controlled multi-center trial[J]. Surg Endosc, 2024, 38(11): 6527-6540. DOI: 10.1007/s00464-024-11069-2.
|
| [6] |
Elterman D, Kaplan SA. Reimagining male lower urinary tract symptoms due to benign prostatic hyperplasia treatment: a new approach to first-line interventional therapy[J]. Eur Urol Focus, 2025: S2405-4569(24)00267-0. DOI: 10.1016/j.euf.2024.12.008.
|
| [7] |
Nguyen AV, Moustafa M, Nguyen DD, et al. Absence of race/ethnicity reporting in clinical trials of true minimally invasive surgical therapies for the treatment of benign prostatic hyperplasia[J]. Urology, 2025, 196: 300-308. DOI: 10.1016/j.urology.2024.09.043.
|
| [8] |
Lama J, Winograd J, Codelia-Anjum A, et al. Recent advancements in prostate catheters and stents for management of benign prostatic hyperplasia[J]. Curr Urol Rep, 2024, 26(1): 9. DOI: 10.1007/s11934-024-01235-3.
|
| [9] |
Hamouda A, Ibrahim A, Corsi N, et al. Use of the Schelin Catheter for transurethral intraprostatic anesthesia prior to Rezūm treatment[J]. Can J Urol, 2024, 31(1): 11802-11808.
|
| [10] |
Raizenne BL, Zheng X, Oumedjbeur K, et al. Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study[J]. World J Urol, 2023, 41(1): 179-188. DOI: 10.1007/s00345-022-04218-6.
|
| [11] |
Kaplan SA, Moss JL, Freedman SJ. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study)[J]. Prostate Cancer Prostatic Dis, 2024, 27(3): 531-536. DOI: 10.1038/s41391-024-00833-z.
|
| [12] |
Rojanasarot S, Cutone B, Durand K, et al. Patients' perspectives on attributes while choosing minimally invasive surgery for benign prostatic hyperplasia procedures: experience from men undergoing water vapor thermal therapy[J]. J Endourol, 2023, 37(5): 575-580. DOI: 10.1089/end.2022.0607.
|
| [13] |
Bouhadana D, Nguyen DD, Schwarcz J, et al. Development of a patient decision aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia[J]. BJU Int, 2021, 127(1): 131-135. DOI: 10.1111/bju.15307.
|
| [14] |
Gatto F, Dabestani S, Bratulic S, et al. Plasma and urine free glycosaminoglycans as monitoring biomarkers in nonmetastatic renal cell carcinoma-a prospective cohort study[J]. Eur Urol Open Sci, 2022, 42: 30-39. DOI: 10.1016/j.euros.2022.06.003.
|
| [15] |
Gatto F, Bratulic S, Jonasch E, et al. Plasma and urine free glycosaminoglycans as monitoring and predictive biomarkers in metastatic renal cell carcinoma: a prospective cohort study[J]. JCO Precis Oncol, 2023, 7: e2200361. DOI: 10.1200/PO.22.00361.
|
| [16] |
Ben-David R, Lidagoster S, Geduldig J, et al. Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes[J]. BJU Int, 2025, 135(3): 473-480. DOI: 10.1111/bju.16556.
|
| [17] |
Ben-David R, Lidagoster S, Geduldig J, et al. The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: a contemporary analysis[J]. Urol Oncol Semin Orig Investig, 2025, 43(1): 66.e9-66.e17. DOI: 10.1016/j.urolonc.2024.08.006.
|
| [18] |
D’Andrea VD, Magnani CJ, Ernandez J, et al. Impact of DNA repair deficiency in the evolving treatment landscape of bladder cancer[J]. Curr Urol Rep, 2024, 26(1): 12. DOI: 10.1007/s11934-024-01242-4.
|
| [19] |
Steel N, Bauer-Staeb CMM, Ford JA, et al. Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the global burden of disease study 2021[J]. Lancet Public Health, 2025, 10(3): e172-e188. DOI: 10.1016/S2468-2667(25)00009-X.
|
| [20] |
Hawkes RE, Marsden AM, Cotterill S, et al. Exposure to behaviour change techniques and self-management tasks in a nationally-implemented digital intervention for type 2 diabetes self-management: Analysis of usage data[J]. Soc Sci Med, 2025, 370: 117858. DOI: 10.1016/j.socscimed.2025.117858.
|
| [21] |
D’Andrea D, Mostafid H, Gontero P, et al. Unmet need in non-muscle-invasive bladder cancer failing Bacillus calmette-guérin therapy: a systematic review and cost-effectiveness analyses from the international bladder cancer group[J]. Eur Urol Oncol, 2025, 8(1): 216-229. DOI: 10.1016/j.euo.2024.10.012.
|